Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
Status:
Terminated
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate changes in weight short and long term with
bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Solvay Pharmaceuticals
Collaborators:
H. Lundbeck A/S Wyeth is now a wholly owned subsidiary of Pfizer